Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization

Clinical and Experimental Immunology

Volumn 153, Issue 3, 2008, Pages 369-375

  Azeredo Coutinho, R B G ^a   Matos, D C S ^a   Armoa G G R ^b   Maia, R M ^b   Schubach, A ^c   Mayrink, W ^d   Mendonca S C F ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto de Technologia em Imunobiologicos   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

American cutaneous leishmaniasis; Cytokines; LACK antigen; Leishmania amazonensis; Vaccine

Indexed keywords

CELL EXTRACT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; LEISHMANIA ANALOG RECEPTOR FOR ACTIVATED C KINASE PROTEIN; LEISHMANIA VACCINE; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; INTERFERON PRODUCTION; LEISHMANIA; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; WHOLE CELL;

EID: 49649107442     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03705.x     Document Type: Article

References (31)

1. Desjeux P. Leishmaniasis. Nat Rev Microbiol 2004 2 : 692.
2. Desjeux P. The increase in risk factors for the leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001 95 : 239 43.
3. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005 366 : 1561 77.
4. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 2006 123 : 423 38.
5. Vélez ID, Gilchrist K, Arbelaez MP et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans R Soc Trop Med Hyg 2005 99 : 593 8.
6. De Luca PM, Mayrink W, Alves CR et al. Evaluation of the stability and immunogenicity of autoclaved and non-autoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 1999 17 : 1179 85.
7. Velez ID, del Pilar Agudelo S, Arbelaez MP et al. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans R Soc Trop Med Hyg 2000 94 : 698 703.
8. De Luca PM, Mayrink W, Santiago MA et al. A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. Acta Trop 2001 80 : 251 60.
9. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005 21 : 244 9.
10. Perez-Jimenez E, Kochan G, Gherardi MM, Esteban M. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect 2006 8 : 810 22.
11. + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997 6 : 541 49.
12. Mougneau E, Altare F, Wakil AE et al. Expression cloning of a protective Leishmania antigen. Science 1995 268 : 563 6.
13. Gurunathan S, Sacks DL, Brown DR et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997 186 : 1137 47.
14. Mendonça SC, Coutinho SG, Amendoeira RR, Marzochi MC, Pirmez C. Human American cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol 1986 64 : 269 76.
15. Telino E, De Luca PM, Matos DC et al. In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes. Clin Exp Immunol 2006 143 : 338 44.
16. Sambrook J, Fritsh EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd edn. New York : Cold Spring Harbor Laboratory Press, 1989.
17. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977 74 : 5463 7.
18. Matos DS, Azeredo-Coutinho RB, Schubach A et al. Differential interferon-gamma production characterizes the cytokine responses to Leishmania and Mycobacterium leprae antigens in concomitant mucocutaneous leishmaniasis and lepromatous leprosy. Clin Infect Dis 2005 40 : e5 12.
19. Locksley RM, Heinzel FP, Sadick MD, Holaday BJ, Gardner KD Jr. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T cell subsets. Ann Inst Pasteur Immunol 1987 138 : 744 9.
20. Kedzierski L, Zhu Y, Handman E. Leishmania vaccines: progress and problems. Parasitology 2006 133 (Suppl S87 112.
21. Mendonça SC, Russell DG, Coutinho SG. Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63). Clin Exp Immunol 1991 83 : 472 8.
22. de Carvalho LP, Soto M, Jeronimo S et al. Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect 2003 5 : 7 12.
23. Farajnia S, Mahboudi F, Ajdari S, Reiner NE, Kariminia A, Alimohammadian MH. Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response. Clin Exp Immunol 2005 139 : 498 505.
24. Campos-Neto A. What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? Braz J Med Biol Res 2005 38 : 979 84.
25. Kelly BL, Stetson DB, Locksley RM. Leishmania major LACK antigen is required for efficient vertebrate parasitization. J Exp Med 2003 198 : 1689 98.
26. Carvalho LP, Passos S, Dutra WO et al. Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients. Scand J Immunol 2005 61 : 337 42.
27. Bacellar O, Lessa H, Schriefer A et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002 70 : 6734 40.
28. Bottrel RL, Dutra WO, Martins FA et al. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun 2001 69 : 3232 9.
29. + T cells generated in response to LACK in naive subjects never exposed to Leishmania. Eur J Immunol 2002 32 : 510 20.
30. Mendonça SC, De Luca PM, Mayrink W et al. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med Hyg 1995 53 : 195 201.
31. Clarencio J, de Oliveira CI, Bomfim G et al. Characterization of the T-cell receptor Vbeta repertoire in the human immune response against Leishmania parasites. Infect Immun 2006 74 : 4757 65.